Document is current
Any future updates will be listed below
-
Authors
Wang, David https://orcid.org/0000-0001-5427-4961
Hung, Noelyn
Hung, Tak
Eden, Karen
Chan, Wing-Kai
Kwan, Rudolf
Qin, Albert
Chang, Cynthia
Duffull, Stephen
Glue, Paul
Jackson, Christopher
-
Funding
Funding for this research was provided by:
University of Otago (Doctoral Scholarship)
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 2 May 2024
First Online: 30 May 2024
Declarations
:
: T.H. is the owner of Zenith Technology Limited contracted to perform the Phase I trial sponsored by Athenex Limited. R.K. was the former Chief Medical Officer of Athenex Limited. W.K.C. was the former Direct of Clinical Trials of Athenex Limited. N.H. is the medical director of Zenith Technology Limited. A.Q. is the Chief Medical Officer of PharmaEssentia Corporation.
